Obesity management in India is shifting toward non-surgical options as bariatric surgery remains expensive and carries risks. Medical solutions include GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), which reduce appetite and promote 15–20% weight loss. Lifestyle interventions—diet, exercise, behavioral therapy, and digital platforms—are increasingly effective when combined with medication. Experts emphasize sustainable habits over quick fixes, with India’s obesity market growing rapidly due to rising diabetes and lifestyle diseases.